The global phosphoinositide kinase inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Phosphoinositide kinase inhibitors restrict PI3K enzymes and help in controlling cancer. The phosphoinositide kinase inhibitors market analysis considers sales from chronic lymphocytic leukaemia (CLL), follicular lymphoma (FL), and other indications. The major factors that are boosting the growth of the global phosphoinositide kinase inhibitors market during the forecast period include the high prevalence of CLL and FL and increasing new cases of cancer.
The cost of PI3K inhibitors is usually high, owing to the complex manufacturing process. This has also had a negative impact on the global phosphoinositide kinase inhibitors market. Therefore, various government bodies have started patient assistance programs to reduce the cost burden on patients and make these treatments available at an affordable price. Thus, the availability of reimbursement programs is expected to fuel the growth of the global phosphoinositide kinase inhibitors market size during the forecast period. The global phosphoinositide kinase inhibitors market analysis includes some of the key market players such as Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.
Market Coverage
Competitive Landscape: Bayer AG, Gilead Sciences Inc., Novartis AG, TG Therapeutics Inc., and Verastem Inc., among others.
Key questions addressed by the report
o Recovery Timeline
o Deviation from pre-COVID forecast
o Most affected region and segment
Global Phosphoinositide Kinase Inhibitors Market by Segment
By Types
• CLL - Chronic Lymphocytic Leukemia
• FL - Follicular Lymphoma
• Others
By End-Use
• Hospital
• Research Institutes and Research Institutions
• Clinic
• Other
Global Phosphoinositide Kinase Inhibitors Market by Regional Analysis
North America
Europe
Asia-Pacific
Rest of the World